Table 2.
Management of disease, stratified by disease severity.
|
|
Mild (n=37) | Moderate (n=48) | Severe (n=55) | All (N=140) | P value (between ADa severity group comparison)b | |||||||
| Time since last AD consultation by dermatologist (n=139), n (%) | .10 | |||||||||||
|
|
Within last 6 months | 13 (36) | 16 (33) | 32 (58) | 61 (44) |
|
||||||
|
|
Within last 6-12 months | 4 (11) | 7 (15) | 3 (6) | 14 (10) |
|
||||||
|
|
Within last 1-2 years | 9 (25) | 9 (19) | 6 (11) | 24 (17) |
|
||||||
|
|
More than 2 years ago | 9 (25) | 14 (29) | 14 (26) | 37 (27) |
|
||||||
|
|
Never | 0 (0) | 2 (4) | 0 (0) | 2 (1) |
|
||||||
|
|
Do not know | 1 (3) | 0 (0) | 0 (0) | 1 (1) |
|
||||||
| Use of moisturizers (n=137), n (%) | .45 | |||||||||||
|
|
Daily | 31 (89) | 40 (83) | 50 (93) | 121 (88) |
|
||||||
|
|
At least once a week | 2 (6) | 3 (6) | 3 (6) | 8 (6) |
|
||||||
|
|
Less than once a week | 0 (0) | 1 (2) | 0 (0) | 1 (1) |
|
||||||
|
|
When needed | 2 (6) | 4 (8) | 0 (0) | 6 (4) |
|
||||||
|
|
Never | 0 (0) | 0 (0) | 1 (2) | 1 (1) |
|
||||||
| Moisturizers are recommended by the treating physician (n=137), n (%) | 31 (89) | 42 (89) | 49 (89) | 122 (89) | N/Ac | |||||||
| TCSd group, current or ever used (N=140), n (%)e | ||||||||||||
|
|
Group I | 17 (46) | 22 (45) | 22 (40) | 61 (44) | .79 | ||||||
|
|
Group II | 23 (62) | 38 (79) | 34 (62) | 95 (68) | .12 | ||||||
|
|
Group III or IV | 30 (81) | 37 (77) | 54 (98) | 121 (86) | .004 | ||||||
|
|
Do not know which group | 1 (3) | 2 (4) | 0 (0) | 3 (2) | .33 | ||||||
| Frequency of current TCS use (n=136), n (%) | <.001 | |||||||||||
|
|
Daily | 3 (9) | 8 (17) | 22 (40) | 33 (24) |
|
||||||
|
|
3-5 times a week | 5 (14) | 16 (35) | 18 (33) | 39 (29) |
|
||||||
|
|
1-2 times a week | 9 (26) | 11 (24) | 6 (11) | 26 (19) |
|
||||||
|
|
1-3 times a month | 5 (14) | 6 (13) | 3 (6) | 14 (10) |
|
||||||
|
|
Less than once a month | 13 (37) | 5 (11) | 6 (11) | 24 (18) |
|
||||||
| Periods of proactive use of TCS the last year (n=134), n (%) | .05 | |||||||||||
|
|
Less than 1 month | 5 (15) | 11 (24) | 9 (17) | 25 (19) |
|
||||||
|
|
1-6 months | 5 (15) | 7 (15) | 6 (11) | 18 (14) |
|
||||||
|
|
More than 6 months | 5 (15) | 12 (26) | 24 (44) | 41 (31) |
|
||||||
|
|
No | 19 (56) | 16 (35) | 15 (28) | 50 (37) |
|
||||||
| Reactive use of TCS within the last month (n=131), n (%) | <.001 | |||||||||||
|
|
1 week | 8 (25) | 16 (36) | 9 (16) | 33 (25) |
|
||||||
|
|
2 weeks | 2 (6) | 9 (21) | 2 (4) | 13 (10) |
|
||||||
|
|
3 weeks | 0 (0) | 4 (9) | 4 (7) | 8 (6) |
|
||||||
|
|
All last month | 7 (22) | 10 (23) | 31 (56) | 48 (37) |
|
||||||
|
|
I have not used reactive treatment | 15 (47) | 5 (11) | 9 (16) | 29 (22) |
|
||||||
aAD: atopic dermatitis.
bPearson chi-square test for atopic dermatitis severity group comparison. Significance level 5%.
cN/A: not applicable.
dTCS: topical corticosteroid.
ePearson chi-square tests for AD severity group comparison for each of the TCS groups.